CN101890181A - 一种猪源纤维蛋白胶粉雾剂及其制备方法和应用 - Google Patents
一种猪源纤维蛋白胶粉雾剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN101890181A CN101890181A CN201010200864XA CN201010200864A CN101890181A CN 101890181 A CN101890181 A CN 101890181A CN 201010200864X A CN201010200864X A CN 201010200864XA CN 201010200864 A CN201010200864 A CN 201010200864A CN 101890181 A CN101890181 A CN 101890181A
- Authority
- CN
- China
- Prior art keywords
- pig
- rev
- mins
- solution
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 title claims abstract description 65
- 239000000843 powder Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 241000282898 Sus scrofa Species 0.000 title abstract description 126
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 76
- 239000008176 lyophilized powder Substances 0.000 claims abstract description 68
- 108090000190 Thrombin Proteins 0.000 claims abstract description 44
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000011780 sodium chloride Substances 0.000 claims abstract description 37
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 36
- 108010073385 Fibrin Proteins 0.000 claims abstract description 35
- 102000009123 Fibrin Human genes 0.000 claims abstract description 35
- 229950003499 fibrin Drugs 0.000 claims abstract description 35
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 34
- 239000001632 sodium acetate Substances 0.000 claims abstract description 34
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 34
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 28
- 239000002245 particle Substances 0.000 claims abstract description 28
- 239000001110 calcium chloride Substances 0.000 claims abstract description 23
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 229960004072 thrombin Drugs 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 62
- 238000001556 precipitation Methods 0.000 claims description 52
- 239000000243 solution Substances 0.000 claims description 47
- 210000002381 plasma Anatomy 0.000 claims description 46
- 238000003756 stirring Methods 0.000 claims description 46
- 239000007983 Tris buffer Substances 0.000 claims description 38
- 235000002639 sodium chloride Nutrition 0.000 claims description 36
- 229960002668 sodium chloride Drugs 0.000 claims description 36
- 239000004471 Glycine Substances 0.000 claims description 31
- 239000001509 sodium citrate Substances 0.000 claims description 31
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 31
- 238000002347 injection Methods 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 30
- 238000005374 membrane filtration Methods 0.000 claims description 30
- 239000006228 supernatant Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 108010049003 Fibrinogen Proteins 0.000 claims description 28
- 102000008946 Fibrinogen Human genes 0.000 claims description 28
- 229940012952 fibrinogen Drugs 0.000 claims description 28
- 239000000428 dust Substances 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 239000000654 additive Substances 0.000 claims description 17
- 230000000996 additive effect Effects 0.000 claims description 17
- 238000000746 purification Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 16
- 238000010298 pulverizing process Methods 0.000 claims description 16
- 239000007853 buffer solution Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 15
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 10
- 230000002779 inactivation Effects 0.000 claims description 10
- 239000011550 stock solution Substances 0.000 claims description 10
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 239000006166 lysate Substances 0.000 claims description 9
- 102000009027 Albumins Human genes 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 8
- 238000005243 fluidization Methods 0.000 claims description 8
- 230000023597 hemostasis Effects 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 235000011148 calcium chloride Nutrition 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 238000010612 desalination reaction Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 3
- 238000013132 cardiothoracic surgery Methods 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims description 2
- 238000002682 general surgery Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000011049 filling Methods 0.000 abstract description 4
- 238000012856 packing Methods 0.000 abstract description 2
- 239000002216 antistatic agent Substances 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 229960000281 trometamol Drugs 0.000 abstract 1
- 229940098458 powder spray Drugs 0.000 description 57
- 206010052428 Wound Diseases 0.000 description 27
- 208000027418 Wounds and injury Diseases 0.000 description 26
- 238000012360 testing method Methods 0.000 description 23
- 208000032843 Hemorrhage Diseases 0.000 description 16
- 230000000740 bleeding effect Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241000252983 Caecum Species 0.000 description 10
- 210000004534 cecum Anatomy 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000002439 hemostatic effect Effects 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 239000010408 film Substances 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 241000282894 Sus scrofa domesticus Species 0.000 description 4
- 206010053615 Thermal burn Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010000050 Abdominal adhesions Diseases 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000035049 Blood-Borne Infections Diseases 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000002632 myometrial effect Effects 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 239000009306 yunnan baiyao Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000075 skin burn Toxicity 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010200864.XA CN101890181B (zh) | 2010-06-12 | 2010-06-12 | 一种猪源纤维蛋白胶粉雾剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010200864.XA CN101890181B (zh) | 2010-06-12 | 2010-06-12 | 一种猪源纤维蛋白胶粉雾剂及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101890181A true CN101890181A (zh) | 2010-11-24 |
CN101890181B CN101890181B (zh) | 2014-04-30 |
Family
ID=43099635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010200864.XA Active CN101890181B (zh) | 2010-06-12 | 2010-06-12 | 一种猪源纤维蛋白胶粉雾剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101890181B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111657269A (zh) * | 2020-06-22 | 2020-09-15 | 镇江雷音再生医学科技有限公司 | 纤维蛋白胶用于smile来源人角膜透镜保存前的保护处理方法 |
CN112891610A (zh) * | 2021-01-25 | 2021-06-04 | 上海利康瑞生物工程有限公司 | 猪源纤维蛋白-静电纺丝纳米纤维抗菌止血贴剂及制备方法 |
CN113018423A (zh) * | 2021-03-12 | 2021-06-25 | 上海利康瑞生物工程有限公司 | 一种基于乙醇梯度洗脱的止血材料及其制备方法 |
CN113797325A (zh) * | 2021-09-29 | 2021-12-17 | 复旦大学 | 一种基于气流粉碎技术制备止血材料的方法 |
US20220096708A1 (en) * | 2016-08-15 | 2022-03-31 | Guangzhou Bioseal Biotech Co. Ltd. | Hemostatic compositions and methods of making thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1049456A (zh) * | 1989-08-12 | 1991-02-27 | 莱阳农学院 | 动纤手术胶的配制 |
CN1465398A (zh) * | 2002-07-03 | 2004-01-07 | 辽宁味邦生物制药有限公司 | 一种用于治疗伤口的外用胶原酶软膏 |
US20060088589A1 (en) * | 2004-10-20 | 2006-04-27 | Gorman Anne J | Reinforced absorbable multilayered hemostatic wound dressing |
CN101214391A (zh) * | 2007-12-27 | 2008-07-09 | 广州倍绣生物技术有限公司 | 一种高效生物胶封闭剂及其应用 |
-
2010
- 2010-06-12 CN CN201010200864.XA patent/CN101890181B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1049456A (zh) * | 1989-08-12 | 1991-02-27 | 莱阳农学院 | 动纤手术胶的配制 |
CN1465398A (zh) * | 2002-07-03 | 2004-01-07 | 辽宁味邦生物制药有限公司 | 一种用于治疗伤口的外用胶原酶软膏 |
US20060088589A1 (en) * | 2004-10-20 | 2006-04-27 | Gorman Anne J | Reinforced absorbable multilayered hemostatic wound dressing |
CN101214391A (zh) * | 2007-12-27 | 2008-07-09 | 广州倍绣生物技术有限公司 | 一种高效生物胶封闭剂及其应用 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220096708A1 (en) * | 2016-08-15 | 2022-03-31 | Guangzhou Bioseal Biotech Co. Ltd. | Hemostatic compositions and methods of making thereof |
US11998656B2 (en) * | 2016-08-15 | 2024-06-04 | Guangzhou Bioseal Co., Ltd. | Hemostatic compositions and methods of making thereof |
CN111657269A (zh) * | 2020-06-22 | 2020-09-15 | 镇江雷音再生医学科技有限公司 | 纤维蛋白胶用于smile来源人角膜透镜保存前的保护处理方法 |
CN111657269B (zh) * | 2020-06-22 | 2022-02-08 | 镇江雷音再生医学科技有限公司 | 纤维蛋白胶用于smile来源人角膜透镜保存前的保护处理方法 |
CN112891610A (zh) * | 2021-01-25 | 2021-06-04 | 上海利康瑞生物工程有限公司 | 猪源纤维蛋白-静电纺丝纳米纤维抗菌止血贴剂及制备方法 |
CN113018423A (zh) * | 2021-03-12 | 2021-06-25 | 上海利康瑞生物工程有限公司 | 一种基于乙醇梯度洗脱的止血材料及其制备方法 |
CN113797325A (zh) * | 2021-09-29 | 2021-12-17 | 复旦大学 | 一种基于气流粉碎技术制备止血材料的方法 |
CN113797325B (zh) * | 2021-09-29 | 2023-11-21 | 复旦大学 | 一种基于气流粉碎技术制备止血材料的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101890181B (zh) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4024302B2 (ja) | 微粒子および創傷治療におけるその用途 | |
CN103349791B (zh) | 一种新型微孔医用止血材料及其制备方法 | |
CN101214391B (zh) | 一种高效生物胶封闭剂及其应用 | |
DK2222327T3 (en) | TOPICAL USE AND FORMULATION OF ERYTHROPOIETIN FOR HEALTH CARE | |
CN101890181B (zh) | 一种猪源纤维蛋白胶粉雾剂及其制备方法和应用 | |
CN102526795A (zh) | 壳聚糖基止血海绵及其制备方法 | |
CN1814279A (zh) | 重组人碱性成纤维细胞生长因子凝胶剂及其制备方法 | |
CN105833331A (zh) | 一种可降解生物创伤敷料的制备方法及所得产品 | |
CN112972755B (zh) | 一种基于猪源纤维蛋白原和凝血酶的生物止血材料的制备方法 | |
CN102058886A (zh) | 医用粉雾剂及其应用 | |
CN101507731A (zh) | 壳聚糖宫颈抗菌膜及其制备方法 | |
CN108310450A (zh) | 一种快速喷射成膜的医疗止血材料及应用方法 | |
CN103007337B (zh) | 高分子聚合物敷料和敷料贴 | |
CN107446018B (zh) | 促进伤口愈合的肽及其应用 | |
CN109224123A (zh) | 具有抑制肿瘤作用的纳米羟基磷灰石复合材料及制备方法 | |
CN103536957B (zh) | 一种新型胶原蛋白-β-环糊精缓释敷料及其制备方法 | |
CN106215221A (zh) | 壳寡糖‑明胶‑镁黄长石纳米纤维生物敷料及其制备方法 | |
WO2017181978A1 (zh) | 贻贝粘蛋白产品及其抑制血管炎症的应用 | |
CN111569143B (zh) | 一种蛇毒凝血酶原激活物及基于蛇毒凝血酶原激活物的快速止血材料 | |
CN101757443A (zh) | 一种治疗血友病的中药制剂 | |
JPH10175857A (ja) | 創傷治療剤 | |
WO2017060821A1 (en) | Hemostatic composition | |
CN116942889B (zh) | 一种止血防粘连多肽水凝胶的制备方法 | |
CN209316234U (zh) | 一种载有生物多肽和纳米膜的复合型创口敷料贴 | |
JPH04500799A (ja) | グルタルアルデヒドにより架橋したビニルアセテートとビニルアルコールのコポリマー、その製造方法及びそれをベースとする医薬品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JOHNSON + JOHNSON (CHINA) INVESTMENT CO., LTD. Free format text: FORMER OWNER: GUANGZHOU BEIXIU BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20121217 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510663 GUANGZHOU, GUANGDONG PROVINCE TO: 200030 XUHUI, SHANGHAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20121217 Address after: 200030, International Building, No. 355, Hongqiao Road, Shanghai, Xuhui District, China, 4 floor Applicant after: Johnson (China) Investment Co., Ltd. Address before: Science City Ruitailu high tech Industrial Development Zone, Guangzhou city of Guangdong Province, No. 5 510663 Applicant before: Guangzhou Beixiu Biotechnology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU BEIXIU BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: JOHNSON + JOHNSON (CHINA) INVESTMENT CO., LTD. Effective date: 20140214 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200030 XUHUI, SHANGHAI TO: 510730 GUANGZHOU, GUANGDONG PROVINCE |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140214 Address after: Six, building 510730, block C, middle ear building, 32 gem Road, Guangzhou economic and Technological Development Zone, Guangdong, China Applicant after: Guangzhou Beixiu Biotechnology Co., Ltd. Address before: 200030, International Building, No. 355, Hongqiao Road, Shanghai, Xuhui District, China, 4 floor Applicant before: Johnson (China) Investment Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |